{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T07:40:03Z","timestamp":1747122003518,"version":"3.40.5"},"reference-count":26,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15064","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T12:13:16Z","timestamp":1745842396000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["Azacitidine plus venetoclax for maintenance treatment in intermediate\u2011to\u2011low\u2011risk acute myeloid leukemia: A comparative analysis of clinical outcomes in an observational cohort"],"prefix":"10.3892","volume":"29","author":[{"given":"Danyang","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology, The Affiliated Beijing Luhe Hospital of Capital Medical University, Beijing 101149, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomin","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Beijing Luhe Hospital of Capital Medical University, Beijing 101149, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Beijing Luhe Hospital of Capital Medical University, Beijing 101149, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Beijing Luhe Hospital of Capital Medical University, Beijing 101149, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaoyan","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Beijing Luhe Hospital of Capital Medical University, Beijing 101149, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Beijing Luhe Hospital of Capital Medical University, Beijing 101149, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hebing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Beijing Luhe Hospital of Capital Medical University, Beijing 101149, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"key20250513102212_b1-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"12915","DOI":"10.1182\/blood-2022-168669","article-title":"Risk factors and prediction model of early relapse in acute myeloid leukemia after allogeneic hematopoietic cell transplantation","volume":"140","author":"Yuan","year":"2022","journal-title":"Blood"},{"key":"key20250513102212_b2-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"key":"key20250513102212_b3-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/s41375-022-01591-4","article-title":"Maintenance therapy for acute lymphoblastic leukemia: Basic science and clinical translations","volume":"36","author":"Toksvang","year":"2022","journal-title":"Leukemia"},{"key":"key20250513102212_b4-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: Updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"key":"key20250513102212_b5-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1111\/bjh.19463","article-title":"Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia","volume":"204","author":"Kinsella","year":"2024","journal-title":"Br J Haematol"},{"key":"key20250513102212_b6-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/ajh.25620","article-title":"Maintenance therapy in AML: The past, the present and the future","volume":"94","author":"Molica","year":"2019","journal-title":"Am J Hematol"},{"key":"key20250513102212_b7-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","article-title":"Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells","volume":"91","author":"Tsao","year":"2012","journal-title":"Ann Hematol"},{"key":"key20250513102212_b8-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.3390\/cancers14082025","article-title":"Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients","volume":"14","author":"Garciaz","year":"2022","journal-title":"Cancers"},{"key":"key20250513102212_b9-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"key20250513102212_b10-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","article-title":"How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia","volume":"33","author":"Jonas","year":"2019","journal-title":"Leukemia"},{"key":"key20250513102212_b11-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s11899-016-0348-8","article-title":"Definition of unfit for standard acute myeloid leukemia therapy","volume":"11","author":"Klepin","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"key20250513102212_b12-ol-29-6-15064","first-page":"2289","article-title":"Maintenance therapy in acute myeloid leukemia: Advances and controversies","volume":"108","author":"Senapati","year":"2023","journal-title":"Haematologica"},{"key":"key20250513102212_b13-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"key20250513102212_b14-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: A consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"key20250513102212_b15-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE-Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"key20250513102212_b16-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"key20250513102212_b17-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"key20250513102212_b18-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in Treatment-Na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20250513102212_b19-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1182\/bloodadvances.2022007083","article-title":"Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia","volume":"6","author":"Chua","year":"2022","journal-title":"Blood Adv"},{"key":"key20250513102212_b20-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"890871","DOI":"10.3389\/fonc.2022.890871","article-title":"MRD in Venetoclax-based treatment for AML: Does it really matter?","volume":"12","author":"Bernardi","year":"2022","journal-title":"Front Oncol"},{"key":"key20250513102212_b21-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"5409","DOI":"10.3390\/cancers15225409","article-title":"Treatment of acute myeloid leukemia in older adults","volume":"5","author":"Alsouqi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"key20250513102212_b22-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"2350319","DOI":"10.1080\/16078454.2024.2350319","article-title":"The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: A retrospective study","volume":"29","author":"Xin","year":"2024","journal-title":"Hematology"},{"key":"key20250513102212_b23-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1200\/JCO.21.00242","article-title":"Advances in management for older adults with hematologic malignancies","volume":"39","author":"Rosko","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20250513102212_b24-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1182\/bloodadvances.2020003902","article-title":"Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia","volume":"5","author":"Patel","year":"2021","journal-title":"Blood Adv"},{"key":"key20250513102212_b25-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1002\/ajh.27417","article-title":"Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment","volume":"99","author":"Garciaz","year":"2024","journal-title":"Am J Hematol"},{"key":"key20250513102212_b26-ol-29-6-15064","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of venetoclax and azacitidine in Treatment-Na\u00efve patients with acute myeloid leukemia and IDH1\/2 mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T07:22:20Z","timestamp":1747120940000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,4,28]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15064","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"type":"print","value":"1792-1074"},{"type":"electronic","value":"1792-1082"}],"subject":[],"published":{"date-parts":[[2025,4,28]]}}}